Evidence map›Paper›PMID 25217618›Full record

ArticleBiology open2014

Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.

Charles Vadnais, Peiman Shooshtarizadeh, Charles V Rajadurai, Robert Lesurf, Laura Hulea, Sayeh Davoudi, Chantal Cadieux, Michael Hallett, Morag Park, Alain Nepveu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. CUX1 Facilitates the Development of Oncogenic PropertiesFrontiers in molecular biosciences · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Charles VadnaisGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada.
Peiman ShooshtarizadehGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada.
Charles V RajaduraiGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada.
Robert LesurfGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada McGill Centre for Bioinformatics, McGill University, Montreal, QC H3G 0B1, Canada.
Laura HuleaGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada.
Sayeh DavoudiGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada.
Chantal CadieuxDepartment of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada.
Michael HallettGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada McGill Centre for Bioinformatics, McGill University, Montreal, QC H3G 0B1, Canada.
Morag ParkGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada Department of Oncology, McGill University, Montreal, QC H2W 1S6, Canada.
Alain NepveuGoodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada Department of Oncology, McGill University, Montreal, QC H2W 1S6, Canada alain.nepveu@mcgill.ca.
McGill University · CAMcGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autocrine activation of the Wnt/β-catenin pathway occurs in several cancers, notably in breast tumors, and is associated with higher expression of various Wnt ligands. Using various inhibitors of the FZD/LRP receptor complex, we demonstrate that some adenosquamous carcinomas that develop in MMTV-CUX1 transgenic mice represent a model for autocrine activation of the Wnt/β-catenin pathway. By comparing expression profiles of laser-capture microdissected mammary tumors, we identify Glis1 as a transcription factor that is highly expressed in the subset of tumors with elevated Wnt gene expression. Analysis of human cancer datasets confirms that elevated WNT gene expression is associated with high levels of CUX1 and GLIS1 and correlates with genes of the epithelial-to-mesenchymal transition (EMT) signature: VIM, SNAI1 and TWIST1 are elevated whereas CDH1 and OCLN are decreased. Co-expression experiments demonstrate that CUX1 and GLIS1 cooperate to stimulate TCF/β-catenin transcriptional activity and to enhance cell migration and invasion. Altogether, these results provide additional evidence for the role of GLIS1 in reprogramming gene expression and suggest a hierarchical model for transcriptional regulation of the Wnt/β-catenin pathway and the epithelial-to-mesenchymal transition.

Indexed as

Breast cancerExpression profilingMouse tumor modelTranscriptional regulationWnt/β-Catenin pathway

Identifiers

PMID25217618
PMCPMC4197442
OpenAlexW2129558818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.